Press releases

Press releases

03 May 2016  - Paris (France)

Oncodesign and Ipsen enter into a strategic partnership in oncology and Oncodesign joins Ipsen’s Paris-Saclay Campus

28 April 2016  - Paris (France)

Ipsen’s first quarter 2016 sales up 4.7%

26 April 2016  - Paris (France)

Probi and Ipsen sign extensive Primary Care distribution agreement for probiotic LP299V®, Lactobacillus plantarum 299v

26 April 2016  - Paris (France)

Ipsen is pleased to announce that its partner Exelixis obtained FDA Approval of CABOMETYX™ (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy

05 April 2016  - Paris (France)

Dassault Systèmes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen’s drug discovery

31 March 2016  - Paris (France)

The Ipsen Group publishes its 2015 Registration Document

08 March 2016  - Paris (France)

Ipsen and PeptiMimesis announce a research partnership in oncology

01 March 2016  - Paris (France)

Ipsen’s 2015 results and 2016 financial objectives

01 March 2016  - Paris (France)

Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy Cabozantinib in regions outside the United States, Canada and Japan

17 February 2016  - Paris (France)

Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology

Updated on 01 March 2016